Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29200978 | 0.92 | KDM4E (0.49) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL1871485 | 0.91 | ALDH1A1 (0.50) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL15910642 | 0.89 | PIK3CD (0.47) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL3358945 | 0.88 | ALOX15 (0.52) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL3369338 | 0.86 | PIK3CD (0.43) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL3358324 | 0.85 | KDM4E (0.41) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL27083924 | 0.85 | CHEK1 (0.44) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL3353482 | 0.84 | CHEK1 (0.42) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL30271240 | 0.84 | CHEK1 (0.42) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL3352334 | 0.84 | HTR2A (0.45) | CHEK1AURKADAPK3CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332950-A | Indazole substituted podophyllotoxin derivative and preparation method and application thereof | 汤亚杰 | 2023-06-27 | — | — | CN | claimed |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4719391-A2 | TRIPLE KINASE INHIBITORS | Unogen Biotech Ltd. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2024254490-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | ACRIVON THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024249831-A2 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-116332950-A | Indazole substituted podophyllotoxin derivative and preparation method and application thereof | 汤亚杰 | 2023-06-27 | — | — | CN | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | CHEK1 108/4885AURKA 220/4885DAPK3 193/4885 |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | CHEK1 3083/4885AURKA 2975/4885DAPK3 841/4885 |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | CHEK1 4745/4885AURKA 4813/4885DAPK3 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.